COX-2 overexpression as a biomarker of early cervical carcinogenesis: A pilot study

Gynecologic Oncology

Volumn 107, Issue 1 SUPPL., 2007, Pages

  Saldivar, J Salvador ^a   Lopez, David ^d   Feldman, Rebecca A ^c   Tharappel Jacob, Reena ^e   de la Rosa, Antonio ^e   Terreros, Daniel ^b   Baldwin, William S ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Paul L Foster School of Medicine   (United States)

^c UNIVERSITY OF TEXAS AT EL PASO   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cervical cancer; Cervical intraepithelial neoplasia; COX 2; Inflammation

Indexed keywords

BIOLOGICAL MARKER; CYCLOOXYGENASE 2;

ADULT; AGED; ARTICLE; CANCER RISK; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; VIRUS INFECTION; WART VIRUS;

ADULT; AGED; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; FEMALE; HELA CELLS; HUMANS; INFLAMMATION; LINEAR MODELS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PILOT PROJECTS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 34748923100     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.07.023     Document Type: Article

References (35)

1. Zha S., Yegnasubramanian V., and Nelson W.G. Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215 (2004) 1-20
2. Bosch F.X., Manos M.M., Munoz N., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 87 (1995) 796-802
3. Ho G.Y., Bierman R., Beardsley L., et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338 (1998) 423-428
4. Castle P.E., and Giuliano A.R. Chapter 4: genital tract infections, cervical inflammation, and antioxidant nutrients-assessing their roles as human papillomavirus cofactors. J Natl Cancer Inst Monogr 31 (2003) 29-34
5. Castle P.E. Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J Low Genit Tract Dis 8 3 (2004) 224-230
6. Castle P.E., Hillier S.L., Rabe L.K., et al. An association of cervical inflammation with high grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV). Cancer Epidemiol Biomarkers Prev 10 (2001) 1021-1027
7. Ames B.N., Gold L.S., and Willett W.C. The causes and prevention of cancer. Proc Natl Acad Sci U S A 92 (1995) 5258-5265
8. Anttila T., Saikku P., Koskela P., et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 285 (2001) 47-51
9. Smith J.S., Herrero R., Bosetti C., et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 94 (2002) 1604-1613
10. Kulkarni S., Rader J.S., Zhang F., et al. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin Cancer Res 7 (2001) 429-434
11. 2 synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 86 5 (2001) 2243-2249
12. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60 (2000) 1306-1311
13. Umar A., Viner J.L., Anderson W.F., et al. Development of COX inhibitors in cancer prevention and therapy. Am J Clin Oncol 26 4 Suppl 2 (2003) S48-S57
14. Steele V.E., Hawk E.T., Viner J.L., and Lubet R.A. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res 523-524 (2003) 137-144
15. Powell M.A., Pfeifer J.D., Buttin B.S., et al. A pilot study of celecoxib in the treatment of patients with cervical and vaginal intraepithelial neoplasia. ASCO Annual Meeting (2003) Abstract 1830
16. Farley J.H., Truong V., McBroom J., et al. A randomized double-blind phase II evaluation of the cyclooxygenase-2 protein inhibitor celecoxib in treating severe dysplasia of the cervix. ASCO Annual Meeting (2005) Abstract 5106
17. Solomon D., Davey D., Kurman R., et al., Forum Group Members. Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287 16 (2002) 2114-2119
18. Qureshi M.N., Rudelli R.D., Tubbs R.R., et al. Role of HPV DNA testing in predicting cervical intraepithelial lesions: comparison of HC HPV and ISH HPV. Diagn Cytopathol 29 3 (2003) 149-155
19. Simon P., Buxant F., Hallez S., et al. Cervical response to vaccination against HPV16 E7. Eur J Obstet Gynecol Reprod Biol 109 2 (2003) 219-223
20. Kobayashi A., Darragh T., Herndier B., et al. Lymphoid follicles are generated in high-grade cervical dysplasia and have differing characteristics depending on HIV status. Am J Pathol 160 1 (2002) 151-164
21. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
22. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 680
23. Coussens L.M., Raymond W.W., Bergers G., et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogensis. Genes Dev 13 (1999) 1382
24. Benitez-Bribiesca L., Wong A., Utrera D., et al. The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem 49 (2001) 1061
25. Peppelenbosch M.P., Tertoolen L.G., Hage W.J., et al. Epidermal growth factor-induced actin remodeling is regulated by 5-lipoxygenase and cyclooxygenase products. Cell 74 (1993) 565-575
26. Greenberg M.D., Reid R., Schiffman M., et al. A prospective study of biopsy-confirmed cervical intraepithelial neoplasia grade 1: colposcopic, cytological, virological risk factors for progression. J Low Genit Tract Dis 3 (1999) 104-110
27. Jones C.J., Brinton L.A., Hamman R.F., et al. Risk factors for in situ cervical cancer: results from a case-control study. Cancer Res 50 (1990) 3657-3662
28. Belkaid Y., and Rouse B.T. Natural regulatory T cells in infectious disease. Nat Immunol 6 4 (2005) 353-360
29. Gall S. Clinical perspectives: targeting the hidden HPV virus. Insight HPV vol. 1 (2005) 1-11. http://www.targethpv.org website http://www.targethpv.org
30. Sarkar A.K., Luna-Tortolero G., Follen M., and Sastry K.J. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. Gynecologic Oncol Suppl 99 (2005) S251-S261
31. Carter J.J., Koustsky L.A., Hughes J.P., et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181 (2000) 1911-1919
32. Gaffney D.K., Holden J., Zempolich K., et al. Elevated COX-2 expression in cervical carcinoma: reduced cause-specific survival and pelvic control. Am J Clin Oncol 24 7 (2001) 443-446
33. Ferrandina G., Lauriola L., Distefano M.G., et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 20 4 (2002) 973-981
34. Landen C.N., Mathur S.P., Creasman W.T., et al. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol 188 5 (2003) 1174-1176
35. Sherman M.E., Wang S.S., Wheeler C.M., et al. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev 12 (2003) 1038-1044